Safety, Tolerability and PK of Single and Multiple Doses of Oxantel Pamoate Tablets (HELP-OXA)

A Placebo Controlled, Double-Blind, 3-Arm Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of 20 mg/kg Oxantel Pamoate in Healthy Adult Volunteers

The goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics of oxantel pamoate tablet after administration of a single and multiple dose in healthy male and female adult volunteers.

The main questions aim to answer if oxantel pamoate is safe and well tolerated in healthy volunteers and if is it absorbed by the human body.

A single dose and a multiple dose of oxantel pamoate will be compared to placebo to see if there are any different effects.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Drug: Placebo; Drug: Oxantel Pamoate

Detailed Description

Objectives:

Primary objective:

To investigate the safety and tolerability of oxantel pamoate after single and multiple oral administration of a chewable tablet formulation.

Secondary objective:

To investigate the pharmacokinetics (PK) of oxantel pamoate after single and multiple oral administration of a chewable tablet formulation.

Study Design:

This is a randomized, placebo controlled, double blind, 3-arm Phase I single centre study in a total of 45 healthy adults. The participants will be randomized into one of the following three study arms:

• Study arm 1, 20 participants: Treatment with single dose of 20 mg/kg oxantel pamoate on day 1 followed by administration of two daily doses placebo
• Study arm 2, 20 participants: Treatment with three daily dose of 20 mg/kg oxantel pamoate
• Study arm 3, 5 participants: Treatment with three daily dose of placebo PK sampling will be performed at 13 defined time points (baseline included).

The participants will be admitted to the ward one day prior to commencement of the study treatment (day -1) and will stay until one day after the last dose has been administered. They will have a final follow-up visit on day 14. The safety and tolerability will be assessed as of the first dosage up to the last follow-up visit. Biochemistry, haematology, coagulation and urinalysis will be checked at baseline, day 3 and at the final follow-up visit.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 1

Contacts and Locations

Study Locations

• Tanzania
  • Bagamoyo, Tanzania
    • Ifakara Health Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy adult male or non-pregnant (confirmed by a negative serum pregnancy test) and non-breastfeeding female participants, aged between 18 to 45 years at the time of consent.
• Written informed consent (IC) obtained before any study procedure.
• Ability to read and write and to understand the participant information sheet and the nature of the trial and any hazards from participating in it (following a test with a maximum of two attempts). Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
• Women of childbearing potential (WOCBP) must agree to use a highly effective form of contraception from at least 28 days prior to first dosage to 30 days after discharge from the ward.
• Normal body weight range (BMI between 18 and 29.9 kg/ m2).

Exclusion Criteria:

• Participation in another clinical trial within 3 months prior to the study, or within 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer (time calculated relative to the last dose in the previous clinical trial).
• Regular daily consumption of more than one liter of xanthine-containing beverages (e.g. tea, coffee, cola or chocolate drinks).
• Regular daily consumption of more than 5 cigarettes daily.
• Use of a prescription medicine during the 28 days before the first dose of trial medication or use of an over-the-counter medicine, during the 7 days before the first dose of trial medication.
• Use of dietary supplements or herbal remedies (such as St John's Wort) known to interfere with the CYP3A4 and/or P-gp metabolic pathway during the 28 days before the first dose of trial medication.
• Therapies which may impact on the interpretation of study results in the opinion of the Investigator.
• Medical, social condition, psychiatric disorder or occupational reasons that, in the judgment of the Investigator, is a contraindication to the protocol, may impair the volunteer's ability to give informed consent or effectively participate in the study, may significantly increase the risk to the volunteer because of participation in the study or may impair interpretation of the study data.
• Blood pressure (BP) and heart rate (HR) in supine position at the screening examination outside the ranges (systolic BP range: 105-136 mm Hg systolic, diastolic BP range: 58-84 mm Hg diastolic; HR range: 56- 96 beats/min).
• Febrile illness within 1 week before the start of study treatment.
• History of relevant diseases of vital organs, of the central nervous system or other organs.
• Known renal or hepatic impairment
• Participants with a history of allergies, non-allergic drug reactions, adverse reaction to any drug, or multiple drug allergies.
• Presence or history of drug or alcohol abuse in the last 10 years.
• Surgery (e.g. stomach bypass) or medical condition that might affect absorption of study drug taken orally.
• Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer's participation in the trial or make it unnecessarily hazardous.
• Relevant pathological abnormalities in the electrocardiogram (ECG) such as a second or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec (corrected interval according to Fridericia's formula).
• Positive test for human immunodeficiency virus (HIV), hepatitis B or C.
• Positive stool or urine test for helminth infestation by Kato-Katz, urine filtration or Baermann test.
• Positive for malaria by thick blood smear (TBS).
• Presence of abnormal physical findings, or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Treatment with a single dose of 20 mg/kg oxantel pamoate followed by administration of two daily doses placebo	Drug: Oxantel Pamoate; Oxantel Pamoate tablet, 250mg
Experimental: Arm 2; Treatment with three daily dose of 20 mg/kg oxantel pamoate	Drug: Oxantel Pamoate; Oxantel Pamoate tablet, 250mg
Placebo Comparator: Arm 3; Treatment with three daily doses of placebo	Drug: Placebo; Placebo tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
General safety (number, frequency, severity, seriousness and duration of adverse events)	Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events, treatment emerging adverse events	After first dosage on day 0 to day 14
Heart rate from baseline	Change of pulse rate from baseline	After first dosage on day 0 to day 14
Blood pressure from baseline	Change of blood pressure from baseline. Systolic and diastolic blood pressure will be assessed	After first dosage on day 0 to day 14
Temperature from baseline	Change of axillary temperature from baseline	After first dosage on day 0 to day 14
Respiratory rate from baseline	Change of respiratory rate from baseline	After first dosage on day 0 to day 14
Creatinine value from baseline	Change of creatinine value from baseline	After first dosage on day 0 to day 14
Alanine aminotransferase value from baseline	Change of alanine aminotransferase value from baseline	After first dosage on day 0 to day 14
Aspartate aminotransferase value from baseline	Change of aspartate aminotransferase value from baseline	After first dosage on day 0 to day 14
Total bilirubin value from baseline	Change of total bilirubin value from baseline	After first dosage on day 0 to day 14
Sodium value from baseline	Change of sodium value from baseline	After first dosage on day 0 to day 14
Potassium value from baseline	Change of potassium value from baseline	After first dosage on day 0 to day 14
Blood urea nitrogen value from baseline	Change of blood urea nitrogen value from baseline	After first dosage on day 0 to day 14
Haemoglobin value from baseline	Change of haemoglobin value from baseline	After first dosage on day 0 to day 14
Red blood cell count from baseline	Change of red blood cell count from baseline	After first dosage on day 0 to day 14
Mean corpuscular volume from baseline	Change of mean corpuscular volume from baseline	After first dosage on day 0 to day 14
Mean corpuscular haemoglobin value from baseline	Change of mean corpuscular haemoglobin value from baseline	After first dosage on day 0 to day 14
Mean corpuscular haemoglobin concentration from baseline	Change of mean corpuscular haemoglobin concentration from baseline	After first dosage on day 0 to day 14
Platelets value from baseline	Change of platelets value from baseline	After first dosage on day 0 to day 14
White blood cell count from baseline	Change of white blood cell count from baseline	After first dosage on day 0 to day 14
Neutrophils value from baseline	Change of neutrophils value from baseline	After first dosage on day 0 to day 14
Lymphocytes value from baseline	Change of lymphocytes value from baseline	After first dosage on day 0 to day 14
Monocytes value from baseline	Change of monocytes value from baseline	After first dosage on day 0 to day 14
Eosinophils value from baseline	Change of eosinophils value from baseline	After first dosage on day 0 to day 14
Basophils value from baseline	Change of basophils value from baseline	After first dosage on day 0 to day 14
Prothrombin time from baseline	Change of prothrombin time value from baseline	After first dosage on day 0 to day 14
Activated partial thromboplastin time from baseline	Change of activated partial thromboplastin time value from baseline	After first dosage on day 0 to day 14
Protein in urine from baseline	Change of proteine in urine from baseline	After first dosage on day 0 to day 14
Blood in urine from baseline	Change of blood in urine from baseline	After first dosage on day 0 to day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax of oxantel pamoate	Peak Plasma Concentration (Cmax) of oxantel pamoate, if detectable	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
Tmax of oxantel pamoate	Time to reach Cmax (Tmax), in case of plasma concentration determined.	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
AUC of oxantel pamoate	Area under the curve (AUC) of the plasma concentration determined.	Plasma samples taken pre-dose -0.5 hours, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
AUC (0-t) of oxantel pamoate	Concentration from time zero to the last quantifiable concentration at time t, in case plasma concentration can be determined.	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
T1/2 of oxantel pamoate	The plasma elimination half-life, In case plasma concentration can be determined.	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
AUC (tau) of oxantel pamoate	The area under the plasma concentration curve over dosing interval, in case plasma concentration can be determined.	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose
AUC (0-∞) of oxantel pamoate	The AUC of the plasma concentration from time zero to infinity with extrapolation of the terminal phase, In case plasma concentration can be determined.	Plasma samples taken pre-dose -0.5 hours prior first dose, then 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after first dose and 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours after third dose

Collaborators and Investigators

• Sponsor: Swiss Tropical & Public Health Institute
• Collaborators: Ifakara Health Institute; Drugs for Neglected Diseases initiative
• Investigators: Study Director: Daniel Paris, MD, PhD, Swiss Tropical & Public Health Institute; Study Chair: Jennifer Keiser, PhD, Swiss Tropical & Public Health Institute; Principal Investigator: Hussein Mbarak, MD, Ifakara Health Insitute, Tanzania

Study record dates

Study Major Dates

• Study Start (Actual): January 27, 2025
• Primary Completion (Actual): April 8, 2025
• Study Completion (Actual): April 8, 2025

Study Registration Dates

• First Submitted: September 12, 2024
• First Submitted That Met QC Criteria: September 19, 2024
• First Posted (Actual): September 23, 2024

Study Record Updates

• Last Update Posted (Estimated): August 28, 2025
• Last Update Submitted That Met QC Criteria: August 27, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: Safety; Pharmacokinetics; Phase I; Tolerability; Parasitic Diseases; Soil transmitted helminths; Neglected Diseases; Trichuriasis; Whipworm
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Infections; Nematode Infections; Helminthiasis; Enoplida Infections; Adenophorea Infections; Pathological Conditions, Signs and Symptoms; Parasitic Diseases; Trichuriasis; Neglected Diseases; Substandard Drugs; Pharmaceutical Preparations; Counterfeit Drugs; oxantel pamoate
• Other Study ID Numbers: P1773-22A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No